Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
83 hedge funds and large institutions have $43.8M invested in Adverum Biotechnologies in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
9% more funds holding
Funds holding: 76 → 83 (+7)
3.62% more ownership
Funds ownership: 0% → 3.62% (+3.6%)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less capital invested
Capital invested by funds: $62.3M → $43.8M (-$18.6M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $63K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.07M |
| 2 |
6CM
683 Capital Management
New York
|
+$817K |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$425K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$420K |
| 5 |
JP Morgan Chase
New York
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.42M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$563K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$500K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$390K |
| 5 |
RA
Royce & Associates
New York
|
-$380K |
ADVM Hedge Fund Activity: Q4 2016 in Review
83 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2016, worth a combined $43.8M — down 30% from $62.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ADVM positions and 7 closed out — a net gain of 8 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.07M. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.42M.
- 83 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2016, up from 76 in Q3 2016.
- Funds reported $43.8M of Adverum Biotechnologies stock for Q4 2016, down 30% quarter-over-quarter.
- 15 funds opened new Adverum Biotechnologies positions in Q4 2016 and 7 closed out, a net change of +8 holders.
- The largest Adverum Biotechnologies buyer in Q4 2016 was Millennium Management, an estimated $1.07M added.
- The largest Adverum Biotechnologies seller in Q4 2016 was BlackRock Fund Advisors, an estimated $1.42M sold.
Based on aggregated 13F filings for Q4 2016.